nach oben

Die Ophthalmologie

Erschienen in:

13.11.2017 | Trockenes Auge | Leitthema

Neue aktuelle und zukünftige Therapieoptionen in der Behandlung des trockenen Auges

verfasst von: Prof. Dr. E. M. Messmer

Erschienen in: Die Ophthalmologie | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das trockene Auge wurde im Mai 2017 vom „Dry Eye Workshop – DEWSII“ neu definiert. Dementsprechend handelt es sich um eine „multifaktorielle Erkrankung der Augenoberfläche, gekennzeichnet durch einen Verlust der Homöostase des Tränenfilms und verbunden mit okulären Symptomen“. Die aktuelle Definition umfasst ätiologische Faktoren wie eine Instabilität und Hyperosmolarität des Tränenfilms, Entzündung und Schädigung der Augenoberfläche sowie – als neuen Aspekt im Vergleich zur alten Definition – neuronale Störungen. Aktuelle und zukünftige Therapieoptionen zielen auf die Behandlung der oben beschriebenen pathogenetischen Ereignisse ab. Neue Tränenersatzprodukte, Medikamente und Instrumente zur Tränenfilmstimulation, innovative antientzündliche Therapien, Medikamente zur Beeinflussung der kornealen Innervation und neue Methoden zur Behandlung der meibom-Drüsen-Dysfunktion stehen bereits jetzt oder in der nahen Zukunft zur Verfügung.

Messmer EM (2015) The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 112:71–81 (quiz 82)PubMedPubMedCentral

Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC (1998) The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17:584–589CrossRefPubMed

Heiligenhaus A, Koch JM, Kruse FE, Schwarz C, Waubke TN (1995) Diagnosis and and differentiation of dry eye disorders. Ophthalmologe 92:6–11PubMed

Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD (2012) Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea 31:472–478CrossRefPubMed

Tong L, Chaurasia SS, Mehta JS, Beuerman RW (2010) Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in singapore. Invest Ophthalmol Vis Sci 51:3449–3454CrossRefPubMed

Jones L, Downie LE, Korb D et al (2017) TFOS DEWS II management and therapy report. Ocul Surf 15:575–628CrossRefPubMed

Barabino S, Rolando M, Nardi M, Bonini S, Aragona P, Traverso CE (2014) The effect of an artificial tear combining hyaluronic acid and tamarind seeds polysaccharide in patients with moderate dry eye syndrome: a new treatment for dry eye. Eur J Ophthalmol 24:173–178CrossRefPubMed

Cohen S, Martin A, Sall K (2014) Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose. Clin Ophthalmol 8:157–164PubMed

Diaz-Valle D, Arriola-Villalobos P, Garcia-Vidal SE et al (2012) Effect of lubricating eyedrops on ocular light scattering as a measure of vision quality in patients with dry eye. J Cataract Refract Surg 38:1192–1197CrossRefPubMed

10.

Doughty MJ (2014) Fluorescein-tear breakup time as an assessment of efficacy of tear replacement therapy in dry eye patients: a systematic review and meta-analysis. Ocul Surf 12:100–111CrossRefPubMed

11.

Lee JH, Ahn HS, Kim EK, Kim TI (2011) Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea 30:175–179CrossRefPubMed

12.

Zhang Y, Potvin R, Gong L (2013) A study of the short-term effect of artificial tears on contrast sensitivity in patients with Sjogren’s syndrome. Invest Ophthalmol Vis Sci 54:7977–7982CrossRefPubMed

13.

Postorino EI, Rania L, Aragona E et al (2017) Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol. https://doi.org/10.5301/ejo.5001011 PubMed

14.

Schmidt TA, Sullivan DA, Knop E et al (2013) Transcription, translation, and function of lubricin, a boundary lubricant, at the ocular surface. JAMA Ophthalmol 131:766–776CrossRefPubMed

15.

Alquraini A, Garguilo S, D’Souza G et al (2015) The interaction of lubricin/proteoglycan 4 (PRG4) with toll-like receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluid. Arthritis Res Ther 17:353CrossRefPubMedPubMedCentral

16.

Iqbal SM, Leonard C, Regmi SC et al (2016) Lubricin/Proteoglycan 4 binds to and regulates the activity of toll-like receptors in vitro. Sci Rep 6:18910CrossRefPubMedPubMedCentral

17.

Lambiase A, Sullivan BD, Schmidt TA et al (2017) A two-week, randomized, double-masked study to evaluate safety and efficacy of Lubricin (150 mug/mL) eye drops versus sodium hyaluronate (HA) 0.18 % eye drops (Vismed(R)) in patients with moderate dry eye disease. Ocul Surf 15:77–87CrossRefPubMed

18.

Kamiya K, Nakanishi M, Ishii R et al (2012) Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond) 26:1363–1368CrossRef

19.

Koh S, Ikeda C, Takai Y, Watanabe H, Maeda N, Nishida K (2013) Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol 57:440–446CrossRefPubMed

20.

Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K (2012) Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology 119:1954–1960CrossRefPubMed

21.

Nakamura M, Imanaka T, Sakamoto A (2012) Diquafosol ophthalmic solution for dry eye treatment. Adv Ther 29:579–589CrossRefPubMed

22.

Shimazaki-Den S, Iseda H, Dogru M, Shimazaki J (2013) Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea 32:1120–1125CrossRefPubMed

23.

Takamura E, Tsubota K, Watanabe H, Ohashi Y (2012) A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol 96:1310–1315CrossRefPubMedPubMedCentral

24.

Kinoshita S, Awamura S, Nakamichi N, Suzuki H, Oshiden K, Yokoi N (2014) A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol 157:576–583.e1CrossRefPubMed

25.

Samudre S, Lattanzio FA Jr., Lossen V et al (2011) Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated. Invest Ophthalmol Vis Sci 52:6265–6270CrossRefPubMedPubMedCentral

26.

Vijmasi T, Chen FY, Balasubbu S et al (2014) Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease. Invest Ophthalmol Vis Sci 55:5401–5409CrossRefPubMedPubMedCentral

27.

Gumus K, Pflugfelder SC (2017) Intranasal tear neurostimulation: an emerging concept in the treatment of dry eye. Int Ophthalmol Clin 57:101–108CrossRefPubMed

28.

Hyden D, Arlinger S (2007) On the sneeze-reflex and its control. Rhinology 45:218–219PubMed

29.

Friedman NJ, Butron K, Robledo N, Loudin J, Baba SN, Chayet A (2016) A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease. Clin Ophthalmol 10:795–804PubMedPubMedCentral

30.

Brinton M, Kossler AL, Patel ZM et al (2017) Enhanced tearing by electrical stimulation of the anterior ethmoid nerve. Invest Ophthalmol Vis Sci 58:2341–2348CrossRefPubMedPubMedCentral

31.

Gumus K, Schuetzle KL, Pflugfelder SC (2017) Randomized controlled crossover trial comparing the impact of sham or Intranasal tear neurostimulation on conjunctival goblet cell degranulation. Am J Ophthalmol 177:159–168CrossRefPubMed

32.

Marsh P, Pflugfelder SC (1999) Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 106:811–816CrossRefPubMed

33.

Pflugfelder SC, Maskin SL, Anderson B et al (2004) A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5 %, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 138:444–457CrossRefPubMed

34.

Baudouin C, de la Maza MS, Amrane M et al (2017) One-year efficacy and safety of 0.1 % cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. https://doi.org/10.5301/ejo.5001002

35.

Leonardi A, Van Setten G, Amrane M et al (2016) Efficacy and safety of 0.1 % cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 26:287–296CrossRefPubMed

36.

Brown MM, Brown GC, Brown HC, Peet J, Roth Z (1960) Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol 2009(127):146–152

37.

Straub M, Bron AM, Muselier-Mathieu A, Creuzot-Garcher C (2016) Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up. Br J Ophthalmol 100:1547–1550CrossRefPubMedPubMedCentral

38.

Wilson SE, Perry HD (2007) Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 114:76–79CrossRefPubMed

39.

Donnenfeld ED, Karpecki PM, Majmudar PA et al (2016) Safety of Lifitegrast ophthalmic solution 5.0 % in patients with dry eye disease: a 1‑year, multicenter, randomized, placebo-controlled study. Cornea 35:741–748CrossRefPubMedPubMedCentral

40.

Semba CP, Torkildsen GL, Lonsdale JD et al (2012) A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 153:1050–1060.e1CrossRefPubMed

41.

Sheppard JD, Torkildsen GL, Lonsdale JD et al (2014) Lifitegrast ophthalmic solution 5.0 % for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology 121:475–483CrossRefPubMed

42.

Tauber J, Karpecki P, Latkany R et al (2015) Lifitegrast ophthalmic solution 5.0 % versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology 122:2423–2431CrossRefPubMed

43.

Takeuchi H, Okuyama K, Konno O et al (2005) Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. Transplant Proc 37:1745–1747CrossRefPubMed

44.

Moscovici BK, Holzchuh R, Sakassegawa-Naves FE et al (2015) Treatment of Sjogren’s syndrome dry eye using 0.03 % tacrolimus eye drop: prospective double-blind randomized study. Cont Lens Anterior Eye 38:373–378CrossRefPubMed

45.

Labbe A, Liang Q, Wang Z et al (2013) Corneal nerve structure and function in patients with non-sjogren dry eye: clinical correlations. Invest Ophthalmol Vis Sci 54:5144–5150CrossRefPubMed

46.

Galor A, Levitt RC, Felix ER, Martin ER, Sarantopoulos CD (2015) Neuropathic ocular pain: an important yet underevaluated feature of dry eye. Eye (Lond) 29:301–312CrossRef

47.

Rosenthal P, Borsook D (2012) The corneal pain system. Part I: the missing piece of the dry eye puzzle. Ocul Surf 10:2–14CrossRefPubMed

48.

Craig JP, Nichols KK, Akpek EK et al (2017) TFOS DEWS II definition and classification report. Ocul Surf 15:276–283CrossRefPubMed

49.

Lambiase A, Micera A, Pellegrini G et al (2009) In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression. Invest Ophthalmol Vis Sci 50:4622–4630CrossRefPubMed

50.

Coassin M, Lambiase A, Costa N et al (2005) Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. Albrecht Von Graefes Arch Klin Exp Ophthalmol 243:151–155CrossRef

51.

Bonini S, Rama P, Olzi D, Lambiase A (2003) Neurotrophic keratitis. Eye (Lond) 17:989–995CrossRef

52.

Jain P, Li R, Lama T, Saragovi HU, Cumberlidge G, Meerovitch K (2011) An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Exp Eye Res 93:503–512CrossRefPubMed

53.

Meerovitch K, Torkildsen G, Lonsdale J et al (2013) Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol 7:1275–1285CrossRefPubMedPubMedCentral

54.

Finis D, Hayajneh J, Konig C, Borrelli M, Schrader S, Geerling G (2014) Evaluation of an automated thermodynamic treatment (LipiFlow(R)) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocul Surf 12:146–154CrossRefPubMed

55.

Greiner JV (2016) Long-Term (3 year) Effects of a single thermal pulsation system treatment on meibomian gland function and dry eye symptoms. Eye Contact Lens 42:99–107CrossRefPubMed

56.

Lane SS, DuBiner HB, Epstein RJ et al (2012) A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea 31:396–404CrossRefPubMed

57.

Craig JP, Chen YH, Turnbull PR (2015) Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 56:1965–1970CrossRefPubMed

58.

Goldberg DJ (2012) Current trends in intense pulsed light. J Clin Aesthet Dermatol 5:45–53PubMedPubMedCentral

59.

Vegunta S, Patel D, Shen JF (2016) Combination therapy of Intense Pulsed Light Therapy and Meibomian Gland Expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea 35:318–322CrossRefPubMed

Titel: Neue aktuelle und zukünftige Therapieoptionen in der Behandlung des trockenen Auges
verfasst von: Prof. Dr. E. M. Messmer
Publikationsdatum: 13.11.2017
Verlag: Springer Medizin
Schlagwörter: Trockenes Auge
IPL
Ciclosporin
Erschienen in: Die Ophthalmologie / Ausgabe 2/2018
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-017-0608-6

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Neue aktuelle und zukünftige Therapieoptionen in der Behandlung des trockenen Auges

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Langzeitergebnisse zur Verträglichkeit eines korallinen Hydroxylapatitimplantats als Bulbusersatz

Candida-Infiltrat in Iris und Linse bei Iritis und Zustand nach Sepsis

Photopsien und Schattensehen bei vorbestehenden Kopf- und Kauschmerzen

Progrediente Ulzerationen der Periorbita

Promotionskolleg

Blepharitiskomponente des trockenen Auges

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde